Detection of miR-122 by fluorescence real-time PCR in blood from patients with chronic hepatitis B and C infections.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
07 2020
Historique:
received: 17 12 2019
revised: 04 03 2020
accepted: 16 03 2020
pubmed: 15 4 2020
medline: 9 9 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

This study aims to determine whether relative miR-122 levels in peripheral blood are correlated with chronic hepatitis B (CHB) and chronic hepatitis C (CHC) virus infection and viral replication to determine whether miR-122 can be a new marker for liver injury. MicroRNA (miRNA) was extracted from the peripheral blood of 20 CHB patients, 20 CHC patients, and 20 healthy controls. The levels of miR-122 were determined using fluorescence real-time reverse transcription PCR. Then, the associations of miR-122 with CHB and CHC were analyzed, and its correlation with other markers of liver function and viral replication were determined. The expression level of miR-122 in patients with CHB was significantly higher when compared to subjects in the control group (P = 0.007) or CHC patients (P = 0.005). Furthermore, the miR-122 level in patients with CHC was somewhat higher when compared to healthy controls (66% higher), but the difference was not statistically significant (P = 0.229). MiR-122 levels were significantly correlated with ALT (correlation coefficient [R] = 0.7, P < 0.001), AST (R = 0.71, P < 0.001), and HBV NA (R = 0.9, P < 0.001). The regression analysis indicated that the AUC of miR-122 levels in the diagnosis of CHB was 0.87, with a sensitivity of 0.8 and a specificity of 0.8. MiR-122 can be used to distinguish healthy persons and patients with CHB infection with high sensitivity and specificity. These present findings presented that the complex and context-specific associations of miR-122 with liver diseases, suggesting that this may be a promising marker for liver injury.

Sections du résumé

BACKGROUND
This study aims to determine whether relative miR-122 levels in peripheral blood are correlated with chronic hepatitis B (CHB) and chronic hepatitis C (CHC) virus infection and viral replication to determine whether miR-122 can be a new marker for liver injury.
METHODS
MicroRNA (miRNA) was extracted from the peripheral blood of 20 CHB patients, 20 CHC patients, and 20 healthy controls. The levels of miR-122 were determined using fluorescence real-time reverse transcription PCR. Then, the associations of miR-122 with CHB and CHC were analyzed, and its correlation with other markers of liver function and viral replication were determined.
RESULTS
The expression level of miR-122 in patients with CHB was significantly higher when compared to subjects in the control group (P = 0.007) or CHC patients (P = 0.005). Furthermore, the miR-122 level in patients with CHC was somewhat higher when compared to healthy controls (66% higher), but the difference was not statistically significant (P = 0.229). MiR-122 levels were significantly correlated with ALT (correlation coefficient [R] = 0.7, P < 0.001), AST (R = 0.71, P < 0.001), and HBV NA (R = 0.9, P < 0.001). The regression analysis indicated that the AUC of miR-122 levels in the diagnosis of CHB was 0.87, with a sensitivity of 0.8 and a specificity of 0.8.
CONCLUSION
MiR-122 can be used to distinguish healthy persons and patients with CHB infection with high sensitivity and specificity. These present findings presented that the complex and context-specific associations of miR-122 with liver diseases, suggesting that this may be a promising marker for liver injury.

Identifiants

pubmed: 32289629
pii: S1043-4666(20)30092-2
doi: 10.1016/j.cyto.2020.155076
pii:
doi:

Substances chimiques

MIRN122 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

155076

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Zhen-Hua Ma (ZH)

Department of Infection, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Cheng-Xue Sun (CX)

Department of Infection, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Hong Shi (H)

Department of Infection, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Jian-Hua Fan (JH)

Department of Infection, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Yu-Guo Song (YG)

Department of Immunology, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Pei-Jun Cong (PJ)

Department of Dermatology, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Xiang-Min Kong (XM)

Department of Pneumology, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China.

Da-Lin Hao (DL)

Department of Infection, The Affiliated Hospital of BeiHua University, JiLin City, Jilin Province 132011, China. Electronic address: haodalin27@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH